The acquisition of 70% equity interest in Kunming Wuhua Health Hospital (Wuhua Hospital), specializing in chronic-disease management and hemodialysis, was officially completed on March 31th, 2017 in China. This marks Fresenius Medical Care’s first successful joint venture (JV) hospital in China, with the aim of providing high-standard renal-care services and chronic-disease management to local community.
Wuhua hospital is a private Grade II hospital located in Wuhua district in the center of Kunming city, the capital of Yunnan province in south-west China. With more than 30 years history, the facility now offers treatments to more than 8,000 chronic-disease patients and 70 dialysis patients. The scope of services includes internal medicine, nephrology, surgery, gynecology, dermatology, traditional Chinese medicine, physiotherapy, stomatology, pharmacy and rheumatology. Functional sections include laboratory, B-ultrasound, radiology and electrocardiogram.
There are 900,000 people living in Wuhua district and 9.8 million residents in Kunming City. Chronic-disease management will be gradually migrated from larger hospital outpatient departments to smaller Grade II hospitals and community hospitals, according to a new policy issued by the China State Council and the National Health and Family Planning Commission.
As the first JV hospital in mainland China, the new Wuhua hospital will continue chronic-disease management whilst improving services, competency enhancement, quality control, and expand the current HD business, including exploring PD and vascular-surgery business opportunities.
As a milestone partnership and best-practice case for China, Fresenius Medical Care will continue to seek collaboration with the public and private sector partners to extend its expertise and services to provide integrated high-standard holistic care to local renal patients while increasing the benefits to more patients.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.